Lilly execs pull down $48M

It's that time of year again: CEO salary time, when we gather round the water cooler to ooh and ahh over our bosses' paychecks. Today, it's Eli Lilly workers who'll have that privilege, thanks to the Indianapolis Star. The top six execs at Lilly garnered $48 million in pay last year, the Star reports.

Who got a raise? CEO John Lechleiter (photo), for one; he took in $13 million last year, up 39 percent from 2007. Of that, $1.34 million was base salary, which bumped up by 17 percent from last year. And he's been CEO only since April. Chairman emeritus Sidney Taurel (photo) also got $13 million, in addition to the $40 million retirement package that awaits him.

Lilly's board gave Lechleiter credit for snatching ImClone Systems out from under Bristol-Myers Squibb's nose in a $6.3 billion buyout. Directors also praised him for the company's operational results: sales grew 9 percent to $18.6 billion, and though the company posted a $2.07 billion loss, that was largely because of ImClone acquisition expenses.

- see the BNet Pharma story
- get more from the Indianapolis Star
- read the AP story on Taurel's retirement

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

THIS WEEK: Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today!

Suggested Articles

North Korean hackers were accused of posing as corporate recruiters in a scheme to breach AstraZeneca's computer systems and steal COVID-19 research.

The FDA has delayed its review of Revance's frown-line injection candidate after it failed to inspect a key manufacturing facility on time.

McKinsey & Company helped guide Purdue's strategy for years and pitched the idea of rebates to distributors for overdoses, according to the NYT.